Please assess the completion status of the following clinical trial:

Trial Title: Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Disease Characteristics:~1. Patient previously diagnosed with multiple myeloma; Durie-Salmon Stage I, II, or III based on standard criteria~2. Progressive disease. For non-secretory multiple myeloma, progressive disease is defined as bone marrow biopsy with \> 25% increase in plasma cells or an absolute increase of at least 10% over prior known level. Alternatively, development of new or worsening of existing lytic bone lesions or soft tissue plasmacytomas, or hypercalcemia (serum calcium \>11.5 mg/dL), or relapse from complete response.~Patient Characteristics:~1. 18 yrs or older~2. Patient has given voluntary written informed consent.~3. Unless post-menopausal or surgically sterilized, a female must be willing to use an acceptable method of birth control~4. Male patient must agree to use an acceptable method for contraception for the duration of the study.~5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.~6. Life expectancy is at least 3 months.~7. • Absolute Neutrophil Count (ANC) over 1,000/ul without the use of colony stimulating factors~   * Platelets over 50,000/ul without transfusion support 7 days~  * Bilirubin 2.0 mg/dl or less~  * aspartate aminotransferase (AST) 4 times or less upper limit normal Prior Therapy for Multiple Myeloma: Patients must have had at least 2 prior therapeutic regimens~Exclusion Criteria:~* Pregnant or breast feeding~* History of allergic reaction to compounds containing boron or mannitol.~* Active uncontrolled viral (including HIV), bacterial, or fungal infection.~* Grade III or IV toxicity due to previous anti-neoplastic therapy~* More than Grade 2 motor or sensory neuropathy~* Myocardial infarction within 6 months of enrollment or New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled arrhythmias, or electrocardiographic evidence of acute ischemia.~* For any patients whose lifetime cumulative doxorubicin dose exceeds 400mg/m2, patients with left ventricular ejection fraction (LVEF) less than 35% by multigated acquisition (MUGA) .~* Concurrent administration of liposomal doxorubicin, melphalan, and bortezomib (single or two drug combinations of these are permissible)~* Less than 3 weeks since most recent chemotherapy or concurrent chemotherapy~* Use of corticosteroids (mroe than 10 mg prednisone/day or equivalent)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Doxil® + Melphalan + Velcade (DMV) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).